EUVIMEDEUVIMED entdecken
MetaanalyseSystematische ÜbersichtOpen Access · CC BY 4.0

Navigating through the PD-1/PDL-1 Landscape: A Systematic Review and Meta-Analysis of Clinical Outcomes in Hepatocellular Carcinoma and Their Influence on Immunotherapy and Tumor Microenvironment

Muhammad Joan Ailia iD, Jeong Heo iD, So Young Yoo iD

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms24076495 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Muhammad Joan Ailia und 2 weiteren Autor:innen. Beteiligte Einrichtung: BIO-IT Foundry Technology Institute, Pusan National University, Busan 46241, Republic of Korea. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pusan National University Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This systematic review aimed to assess the prognostic significance of programmed cell death-ligand 1 (PDL-1) and programmed cell death protein 1 (PD-1) in hepatocellular carcinoma (HCC). Medline, EMBASE, and Cochrane Library database searches were conducted, revealing nine relevant cohort studies (seven PDL-1 and three PD-1). Our meta-analysis showed that PD-1/PDL-1 was a marker of poor survival, regardless of the assessment method (PD-1 overall survival (OS): hazard ratio (HR) 2.40; 95% confidence interval (CI), 1.30–4.42; disease-free survival (DFS): HR 2.12; 95% CI, 1.45–3.10; PDL-1: OS: HR 3.61; 95% CI, 2.75–4.75; and DFS: HR 2.74; 95% CI, 2.09–3.59). Additionally, high level of PD-1/PDL-1 expression was associated with aging, multiple tumors, high alpha-fetoprotein levels, and advanced Barcelona Clinic Liver Cancer stage. This high level significantly predicted a poor prognosis for HCC, suggesting that anti-PD-1 therapy is plausible for patients with HCC. Furthermore, HIF-1 induces PD-1 expression, and PD1lowSOCS3high is associated with a better prognosis. Taken together, combination therapy may be the key to effective immunotherapy. Thus, exploring other markers, such as HIF-1 and SOCS3, along with PD-1/PDL-1 immunotherapy, may lead to improved outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsHumansB7-H1 AntigenBiomarkers, TumorImmunotherapyLigandsTumor MicroenvironmentProgrammed Cell Death 1 Receptor

Stichwörter der Autor:innen

hepatocellular carcinoma (HCC)immune checkpoint inhibitors (ICIs)immunotherapyprogrammed cell death protein 1 (PD-1)programmed cell death-ligand 1 (PDL-1)tumor microenvironment (TME)

Substanzen

B7-H1 AntigenBiomarkers, TumorLigandsProgrammed Cell Death 1 Receptor

Autor:innen und Institutionen

  • BIO-IT Foundry Technology Institute, Pusan National University, Busan 46241, Republic of Korea.
  • Department of Internal Medicine, College of Medicine, Pusan National University and Biomedical Research Institute, Pusan National University Hospital, Busan 49241, Republic of Korea.

ORCID-Profile: Muhammad Joan Ailia, Jeong Heo, So Young Yoo

Förderung

  • Pusan National University Hospital

Zitieren

APA

Ailia, M. J., Heo, J., & Yoo, S. Y. (2023). Navigating through the PD-1/PDL-1 Landscape: A Systematic Review and Meta-Analysis of Clinical Outcomes in Hepatocellular Carcinoma and Their Influence on Immunotherapy and Tumor Microenvironment. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24076495

Vancouver

Ailia MJ, Heo J, Yoo SY. Navigating through the PD-1/PDL-1 Landscape: A Systematic Review and Meta-Analysis of Clinical Outcomes in Hepatocellular Carcinoma and Their Influence on Immunotherapy and Tumor Microenvironment. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24076495

BibTeX
@article{Ailia2023,
  author = {Ailia, Muhammad Joan and Heo, Jeong and Yoo, So Young},
  title = {Navigating through the PD-1/PDL-1 Landscape: A Systematic Review and Meta-Analysis of Clinical Outcomes in Hepatocellular Carcinoma and Their Influence on Immunotherapy and Tumor Microenvironment},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms24076495}
}
Kostenlos starten →